We aimed to explore the role of mitochondrial aldehyde dehydrogenase 2 (ALDH2) in prostate cancer (PCa) patients and provide insights into the tumor immune microenvironment (TME) for those patients undergoing radical radiotherapy.We performed all analyses using R version 3.6.3 and its suitable packages. Cytoscape 3.8.2 was used to establish network of competing endogenous RNAs (ceRNAs).Downregulation of ADLH2 was significantly associated with higher risk of BCR-free survival (HR: 0.40, 95%CI: 0.24-0.68, p = 0.001) and metastasis-free survival (HR: 0.21, 95%CI: 0.09-0.49, p = 0.002). Additionally, ALDH2 repression contributed to significantly shorter BCR-free survival in the TCGA database (HR: 0.55, 95%CI: 0.33-0.93, p = 0.027). For immune checkpoints, patients that expressed a higher level of CD96 had a higher risk of BCR than their counterparts (HR: 1.79, 95%CI: 1.06-3.03, p = 0.032), as well as NRP1 (HR: 2.18, 95%CI: 1.29-3.69, p = 0.005). In terms of the TME parameters, the spearman analysis showed that ALDH was positively associated with B cells (r: 0.13), CD8+ T cells (r: 0.19), neutrophils (r: 0.13), and macrophages (r: 0.17). Patients with higher score of neutrophils (HR: 1.75, 95%CI: 1.03-2.95, p = 0.038), immune score (HR: 1.92, 95%CI: 1.14-3.25, p = 0.017), stromal score (HR: 2.52, 95%CI: 1.49-4.26, p = 0.001), and estimate score (HR: 1.81, 95%CI: 1.07-3.06, p = 0.028) had higher risk of BCR than their counterparts. Our ceRNA network found that PART1 might regulate the expression of ALDH via has-miR-578 and has-miR-6833-3p. Besides, PHA-793887, PI-103, and piperlongumine had better correlations with ALDH2.We found that ALDH2 might serve as a potential biomarker predicting biochemical recurrence for PCa patients.
基金：
National Natural Science Foundation of China (Grant
Nos. 81974099, 82170785, 81974098, 82170784), programs from Science and Technology Department of
Sichuan Province (Grant Nos. 2021YFH0172), Young Investigator Award of Sichuan University 2017
(Grant No. 2017SCU04A17), Technology Innovation Research and Development Project of Chengdu
Science and Technology Bureau (2019-YF05-00296-SN), Sichuan University–Panzhihua science and
technology cooperation special fund (2020CDPZH-4).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类|2 区化学
小类|3 区化学：综合3 区生化与分子生物学
最新[2023]版：
大类|2 区化学
小类|3 区生化与分子生物学3 区化学：综合
第一作者：
第一作者机构：[1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Feng Dechao,Zhu Weizhen,You Jia,et al.Mitochondrial Aldehyde Dehydrogenase 2 Represents a Potential Biomarker of Biochemical Recurrence in Prostate Cancer Patients[J].Molecules (Basel, Switzerland).2022,27(18):doi:10.3390/molecules27186000.
APA：
Feng Dechao,Zhu Weizhen,You Jia,Shi Xu,Han Ping...&Yang Lu.(2022).Mitochondrial Aldehyde Dehydrogenase 2 Represents a Potential Biomarker of Biochemical Recurrence in Prostate Cancer Patients.Molecules (Basel, Switzerland),27,(18)
MLA：
Feng Dechao,et al."Mitochondrial Aldehyde Dehydrogenase 2 Represents a Potential Biomarker of Biochemical Recurrence in Prostate Cancer Patients".Molecules (Basel, Switzerland) 27..18(2022)
化学